GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All conditions

GLP-1 Therapy for Type 2 Diabetes in India — Indian Guideline Use

Last reviewed 12 May 2026 · Indian guideline context

The short answer

GLP-1 receptor agonists are now first-line add-on therapy for type 2 diabetes in India per RSSDI 2024 guidelines, particularly for patients with obesity, cardiovascular disease, or chronic kidney disease. Ozempic (semaglutide) and Mounjaro (tirzepatide) are DCGI-approved for T2D. Evidence shows 1.5-2.5% HbA1c reduction plus cardiovascular benefit. Take the 5-minute Indian-guideline eligibility check.

See if you’re a candidate

The 5-minute Indian-guideline eligibility check factors in your Type 2 Diabetes status.

Take the free assessment →

Type 2 Diabetes in India — the context

India has the world's second-largest diabetes population (101 million adults per ICMR-INDIAB 2023), with strong genetic predisposition for early-onset T2D at lower BMI than Western populations. The Asian Indian phenotype — visceral obesity, insulin resistance, and beta-cell dysfunction — makes GLP-1 particularly suitable as a class. RSSDI (Research Society for the Study of Diabetes in India) 2024 guidelines position GLP-1 RAs as preferred add-on for patients with obesity-comorbid T2D and for those with established or high-risk ASCVD (atherosclerotic cardiovascular disease).

How GLP-1 helps — mechanism + evidence

GLP-1 receptor agonists stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. In T2D, this delivers ~1.5-2.5% HbA1c reduction, modest weight loss (3-15% depending on agent), and importantly — for semaglutide (Ozempic) — a 26% reduction in major adverse cardiovascular events (MACE) in the SUSTAIN-6 trial, and 20% reduction in MACE in the SELECT trial (in patients with obesity + CVD). Tirzepatide (Mounjaro) showed even stronger HbA1c and weight outcomes in SURPASS trials.

Key trials

  • SUSTAIN-6: Semaglutide reduced major adverse cardiovascular events (MACE) by 26% over 2 years in T2D patients with CVD history or high risk.
  • SUSTAIN 1-5: Semaglutide consistently delivered HbA1c reductions of 1.5-2.0% vs comparators (placebo, sitagliptin, exenatide, insulin glargine).
  • SURPASS-2: Tirzepatide vs semaglutide (1 mg) in T2D — tirzepatide superior on both HbA1c (-2.3% vs -1.9%) and weight loss (-11.2 kg vs -5.7 kg) at 40 weeks.
  • SELECT: Semaglutide 2.4 mg reduced MACE by 20% over 3+ years in patients with obesity + established CVD (without diabetes).
  • LEADER (liraglutide): Liraglutide showed 13% MACE reduction in T2D patients — established the cardiovascular-benefit class effect for GLP-1.

Eligibility — who fits?

Per RSSDI/ESI 2024 guidelines, GLP-1 add-on therapy is preferred for T2D patients with: HbA1c above target on metformin + lifestyle; BMI ≥27.5 (or ≥25 with comorbidity); established or high-risk ASCVD; or chronic kidney disease. The 5-minute GLP-1 Check assessment factors in HbA1c, BMI, comorbidities, and current therapies to map your fit. Note: GLP-1 is generally not used in type 1 diabetes.

Indian-context considerations

  • •Concurrent insulin or sulfonylurea: dose adjustment may be needed to reduce hypoglycaemia risk when adding GLP-1
  • •Renal function: most GLP-1 RAs are safe in mild-moderate CKD; Ozempic is renal-friendly with no dose adjustment needed
  • •Indian diet patterns (high-carb, rice-heavy, late dinners) — pair GLP-1 with carb timing changes for best HbA1c outcomes
  • •Cost vs HbA1c-equivalent alternatives: Indian generic semaglutides are cost-effective at ₹1,290–3,500/month vs ₹5,660+/month for Ozempic
  • •Cardiovascular protection benefit (SUSTAIN-6, SELECT) is specific to semaglutide — discuss with endocrinologist if CVD risk reduction is a primary goal

Brand options for Type 2 Diabetes

Ozempic

DCGI-approved for T2D. Strongest evidence base for cardiovascular protection (SUSTAIN-6, SELECT). Once-weekly injection.

Mounjaro

DCGI-approved for T2D. Strongest HbA1c reduction and weight loss outcomes (SURPASS trials). Dual GIP+GLP-1 agonist.

Sematrinity (Sun Pharma)

Indian generic semaglutide for T2D indication. Cost-effective sustained-therapy option at ₹1,290–2,000/month.

Full brand catalog: Semaglutide brands in India → · India pricing →

Patient pathway

Typical T2D pathway: (1) take the 5-min GLP-1 Check assessment to map fit and current control; (2) endocrinology consult (most NCR, Mumbai, Pune, Jaipur specialists have extensive GLP-1 prescribing experience for T2D); (3) baseline labs (HbA1c, fasting glucose, lipid profile, LFT, KFT, CGM if available); (4) discuss agent choice — Ozempic if CV-protection priority, Mounjaro if maximum HbA1c + weight outcomes priority, Indian generic if cost-sensitive; (5) titrate over 12-16 weeks; (6) monthly follow-ups for first 3 months, then quarterly.

Frequently asked questions

Is Ozempic approved for diabetes in India?+
Yes — Ozempic (semaglutide) is DCGI-approved for type 2 diabetes in India. It is one of the first-line GLP-1 RAs prescribed for T2D, particularly for patients with obesity, cardiovascular disease, or chronic kidney disease.
How much will my HbA1c drop on GLP-1?+
Average HbA1c reduction in trials: semaglutide 1.0 mg dose ~1.4%, 2.0 mg dose ~1.8%; tirzepatide 15 mg ~2.3%. Real-world results vary based on baseline HbA1c, adherence, diet, and concurrent therapies. Patients with higher baseline HbA1c (>9%) often see larger absolute reductions.
Can I replace insulin with GLP-1?+
Sometimes — but only with your endocrinologist's direct supervision. In some T2D patients on basal insulin with overweight/obesity, transitioning to GLP-1 + basal-insulin combination, or to GLP-1 alone, is possible. Never stop insulin without medical guidance — abrupt discontinuation can cause severe hyperglycaemia and DKA risk.
Are there cardiovascular benefits to GLP-1 for diabetes?+
Yes, for semaglutide and liraglutide. The SUSTAIN-6 trial showed 26% MACE reduction with semaglutide in T2D patients with CVD; LEADER showed 13% MACE reduction with liraglutide. The SELECT trial extended benefit to patients with obesity + CVD without diabetes (20% MACE reduction with semaglutide 2.4 mg). Tirzepatide CV outcomes trial (SURPASS-CVOT) results expected 2026-2027.
Is GLP-1 covered by Indian health insurance for T2D?+
Coverage varies. Some private health insurance policies (notably those with chronic-disease riders) cover GLP-1 for diabetes when prescribed by an endocrinologist. Government schemes (CGHS, ECHS, ESI) have inconsistent coverage. Check with your insurer; for outpatient management, most patients pay out-of-pocket unless they have specific diabetes care riders.
Which is better for diabetes — Ozempic or Mounjaro?+
Mounjaro typically delivers stronger HbA1c reduction and weight loss (SURPASS-2: tirzepatide 1 mg dose lost more than semaglutide 1 mg dose). Ozempic has stronger long-term cardiovascular outcome evidence (SUSTAIN-6, SELECT). For most patients with obesity + T2D + CVD, the choice comes down to: weight + glycaemic priority → Mounjaro; cardiovascular protection priority → Ozempic. Discuss with your endocrinologist.
What's the cheapest GLP-1 for diabetes in India?+
Indian generic semaglutides for the T2D indication: Sematrinity (Sun Pharma), Glipiq, others — typically ₹1,290–2,000/month. These are dramatically cheaper than Ozempic (₹5,660+/month). Clinical efficacy is the same molecule (semaglutide); differences are in pen design, dose flexibility, and manufacturer brand trust.

Related conditions

PCOS

GLP-1 for PCOS — Indian context

Prediabetes

GLP-1 for Prediabetes — Indian context

Fatty Liver (NAFLD/MASLD)

GLP-1 for Fatty Liver (NAFLD/MASLD) — Indian context

Hypertension

GLP-1 for Hypertension — Indian context

See if GLP-1 fits your Type 2 Diabetes profile

5 minutes. Uses your BMI, comorbidities, and lab values (optional) to recommend an evidence-based starting point.

Take the free assessment →

Educational content based on DCGI-approved labelling, peer-reviewed trials, RSSDI/ESI/INASL Indian clinical guidelines, and published literature. Not a substitute for a doctor’s clinical judgment. GLP-1 therapies are Schedule H drugs in India and require a doctor’s prescription. Always consult a qualified medical practitioner before starting any therapy.